Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Niagen Bioscience, Inc. (NAGE : NSDQ)

• Company Description    Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $11.79 Daily Weekly Monthly 20 Day Moving Average: 962,833 shares Shares Outstanding: 78.77 (millions) Market Capitalization: $928.69 (millions) Beta: 2.14 52 Week High: $14.69 52 Week Low: $2.52 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.62% -19.74% 12 Week 74.41% 46.70% Year To Date 122.24% 108.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10900 Wilshire Blvd. Suite 600 - Los Angeles,CA 90024 USA ph: 310-388-6706 fax: 949-419-0294 shamsian@lythampartners.com http://www.niagenbioscience.com

• General Corporate Information    Officers Robert Fried - Chief Executive Officer and Director Frank Jaksch - Chairman of the Board and Director Ozan Pamir - Chief Financial Officer Steven Rubin - Director Wendy Yu - Director Peer Information Niagen Bioscience, Inc. (CORR.) Niagen Bioscience, Inc. (RSPI) Niagen Bioscience, Inc. (CGXP) Niagen Bioscience, Inc. (BGEN) Niagen Bioscience, Inc. (GTBP) Niagen Bioscience, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 171077407 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 78.77 Most Recent Split Date: 4.00 (0.33:1) Beta: 2.14 Market Capitalization: $928.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.13 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: 93.08 Trailing 12 Months: 131.00 PEG Ratio: - Price Ratios Price/Book: 16.76 Price/Cash Flow: 199.33 Price / Sales: 8.61 EPS Growth vs. Year Ago Period: 500.00% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: 37.59% vs. Previous Quarter: 4.66% ROE 06/30/25 - - 03/31/25 - 19.06 12/31/24 - 10.57 ROA 06/30/25 - - 03/31/25 - 12.20 12/31/24 - 6.36 Current Ratio 06/30/25 - - 03/31/25 - 3.66 12/31/24 - 3.57 Quick Ratio 06/30/25 - - 03/31/25 - 3.12 12/31/24 - 3.06 Operating Margin 06/30/25 - - 03/31/25 - 7.35 12/31/24 - 3.72 Net Margin 06/30/25 - - 03/31/25 - 13.07 12/31/24 - 8.58 Pre-Tax Margin 06/30/25 - - 03/31/25 - 13.51 12/31/24 - 8.89 Book Value 06/30/25 - - 03/31/25 - 0.70 12/31/24 - 0.60 Inventory Turnover 06/30/25 - - 03/31/25 - 3.81 12/31/24 - 3.48 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©